Compare ALEMBIC PHARMA with - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALEMBIC PHARMA vs ALKEM LABORATORIES - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALEMBIC PHARMA ALKEM LABORATORIES ALEMBIC PHARMA/
ALKEM LABORATORIES
 
P/E (TTM) x 17.1 22.2 77.0% View Chart
P/BV x 6.8 5.3 126.8% View Chart
Dividend Yield % 0.6 0.9 62.0%  

Financials

 ALEMBIC PHARMA   ALKEM LABORATORIES
EQUITY SHARE DATA
    ALEMBIC PHARMA
Mar-19
ALKEM LABORATORIES
Mar-20
ALEMBIC PHARMA/
ALKEM LABORATORIES
5-Yr Chart
Click to enlarge
High Rs6642,720 24.4%   
Low Rs4121,660 24.8%   
Sales per share (Unadj.) Rs208.7697.9 29.9%  
Earnings per share (Unadj.) Rs31.096.1 32.2%  
Cash flow per share (Unadj.) Rs37.1117.3 31.6%  
Dividends per share (Unadj.) Rs5.5025.00 22.0%  
Dividend yield (eoy) %1.01.1 89.5%  
Book value per share (Unadj.) Rs144.2515.2 28.0%  
Shares outstanding (eoy) m188.52119.57 157.7%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.63.1 82.2%   
Avg P/E ratio x17.422.8 76.2%  
P/CF ratio (eoy) x14.518.7 77.6%  
Price / Book Value ratio x3.74.3 87.8%  
Dividend payout %17.726.0 68.2%   
Avg Mkt Cap Rs m101,461261,879 38.7%   
No. of employees `000NA14.3 0.0%   
Total wages/salary Rs m7,46715,055 49.6%   
Avg. sales/employee Rs ThNM5,822.6-  
Avg. wages/employee Rs ThNM1,050.5-  
Avg. net profit/employee Rs ThNM802.0-  
INCOME DATA
Net Sales Rs m39,34783,444 47.2%  
Other income Rs m941,042 9.0%   
Total revenues Rs m39,44184,486 46.7%   
Gross profit Rs m8,73614,734 59.3%  
Depreciation Rs m1,1522,528 45.6%   
Interest Rs m184651 28.3%   
Profit before tax Rs m7,49312,598 59.5%   
Minority Interest Rs m110-   
Prior Period Items Rs m-930-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,5681,105 141.9%   
Profit after tax Rs m5,84411,493 50.8%  
Gross profit margin %22.217.7 125.7%  
Effective tax rate %20.98.8 238.5%   
Net profit margin %14.913.8 107.8%  
BALANCE SHEET DATA
Current assets Rs m19,57754,960 35.6%   
Current liabilities Rs m14,89632,433 45.9%   
Net working cap to sales %11.927.0 44.1%  
Current ratio x1.31.7 77.6%  
Inventory Days Days9080 112.8%  
Debtors Days Days4572 62.9%  
Net fixed assets Rs m27,09732,710 82.8%   
Share capital Rs m377239 157.7%   
"Free" reserves Rs m26,81161,368 43.7%   
Net worth Rs m27,18861,607 44.1%   
Long term debt Rs m4,9931,592 313.6%   
Total assets Rs m47,77899,433 48.0%  
Interest coverage x41.720.4 204.8%   
Debt to equity ratio x0.20 710.5%  
Sales to assets ratio x0.80.8 98.1%   
Return on assets %12.612.2 103.3%  
Return on equity %21.518.7 115.2%  
Return on capital %23.621.0 112.6%  
Exports to sales %019.1 0.0%   
Imports to sales %03.0 0.0%   
Exports (fob) Rs mNA15,917 0.0%   
Imports (cif) Rs mNA2,483 0.0%   
Fx inflow Rs m19,45316,061 121.1%   
Fx outflow Rs m6,0652,483 244.3%   
Net fx Rs m13,38813,578 98.6%   
CASH FLOW
From Operations Rs m8,1205,851 138.8%  
From Investments Rs m-7,556-7,414 101.9%  
From Financial Activity Rs m590792 74.6%  
Net Cashflow Rs m1,153-731 -157.7%  

Share Holding

Indian Promoters % 74.1 66.9 110.8%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 2.9 33.1 8.8%  
FIIs % 9.1 0.0 -  
ADR/GDR % 0.0 0.0 -  
Free float % 13.9 0.0 -  
Shareholders   49,328 68,381 72.1%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALEMBIC PHARMA With:   DIVIS LABORATORIES  WOCKHARDT  ALEMBIC  NATCO PHARMA  ELDER PHARMA  

Compare ALEMBIC PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Zooms 661 Points, Nifty Ends Above 14,500; M&M and Bajaj Finserv Top Gainers(Closing)

Indian share markets witnessed most of the buying interest during closing hours today and ended on a strong note.

Related Views on News

ALEMBIC PHARMA Announces Quarterly Results (3QFY21); Net Profit Up 13.8% (Quarterly Result Update)

Jan 19, 2021 | Updated on Jan 19, 2021

For the quarter ended December 2020, ALEMBIC PHARMA has posted a net profit of Rs 3 bn (up 13.8% YoY). Sales on the other hand came in at Rs 13 bn (up 8.7% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

ALEMBIC PHARMA Announces Quarterly Results (2QFY21); Net Profit Up 30.0% (Quarterly Result Update)

Oct 23, 2020 | Updated on Oct 23, 2020

For the quarter ended September 2020, ALEMBIC PHARMA has posted a net profit of Rs 3 bn (up 30.0% YoY). Sales on the other hand came in at Rs 15 bn (up 17.4% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

ALEMBIC PHARMA Announces Quarterly Results (3QFY20); Net Profit Up 33.3% (Quarterly Result Update)

Jan 23, 2020 | Updated on Jan 23, 2020

For the quarter ended December 2019, ALEMBIC PHARMA has posted a net profit of Rs 2 bn (up 33.3% YoY). Sales on the other hand came in at Rs 12 bn (up 18.8% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

ALEMBIC PHARMA Announces Quarterly Results (2QFY20); Net Profit Up 25.2% (Quarterly Result Update)

Nov 1, 2019 | Updated on Nov 1, 2019

For the quarter ended September 2019, ALEMBIC PHARMA has posted a net profit of Rs 3 bn (up 25.2% YoY). Sales on the other hand came in at Rs 12 bn (up 10.1% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

ALEMBIC PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 36.4% (Quarterly Result Update)

Aug 21, 2019 | Updated on Aug 21, 2019

For the quarter ended June 2019, ALEMBIC PHARMA has posted a net profit of Rs 1 bn (up 36.4% YoY). Sales on the other hand came in at Rs 9 bn (up 10.0% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

More Views on News

Most Popular

India: Recovery Stalled by Vaccine Games?(The Honest Truth)

Apr 13, 2021

Ajit Dayal on how India's vaccine strategy will impact the markets.

4 Stocks to Make Your Portfolio Immune to the Second Covid Wave(Profit Hunter)

Apr 6, 2021

Rather than predicting the market, successful investing is more about preparing well and placing your bets accordingly.

If the Market Falls, I Will Do This...(Fast Profits Daily)

Apr 1, 2021

What should you do if the market falls? In this video, I'll tell you what I will do.

The Indian Real Estate Party Has Just Begun(Profit Hunter)

Apr 1, 2021

A favourable demand supply scenario makes a strong case for real estate prices.

The Dilemma of Investing in Bharti Airtel(Views On News)

Apr 1, 2021

Rahul Shah on whether Bharti Airtel will emerge as the next big thing in the Indian stock market

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

ALEMBIC PHARMA SHARE PRICE


Apr 13, 2021 (Close)

TRACK ALEMBIC PHARMA

  • Track your investment in ALEMBIC PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALEMBIC PHARMA

ALEMBIC PHARMA 5-YR ANALYSIS

COMPARE ALEMBIC PHARMA WITH

MARKET STATS